Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and assigns a Buy rating with a ...
Wells Fargo analyst Vik Chopra maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $76 t...
Globus Medical (NYSE:GMED) affirms FY2025 Adj EPS guidance from $3.00-$3.30 to $3.00-$3.30 vs $3.16 analyst estimate. Affirms F...
Globus Medical (NYSE:GMED) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.76 by...
Canaccord Genuity analyst William Plovanic maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from ...
Needham analyst David Saxon reiterates Globus Medical (NYSE:GMED) from Hold to Hold.
